Page last updated: 2024-09-02

3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide and Body Dysmorphic Disorders

3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide has been researched along with Body Dysmorphic Disorders in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Booij, J; Denys, D; Figee, M; Planting, RS; Vulink, NC1

Other Studies

1 other study(ies) available for 3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide and Body Dysmorphic Disorders

ArticleYear
Reduced striatal dopamine D2/3 receptor availability in Body Dysmorphic Disorder.
    European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2016, Volume: 26, Issue:2

    Topics: Adult; Benzamides; Body Dysmorphic Disorders; Case-Control Studies; Corpus Striatum; Dopamine Antagonists; Female; Humans; Image Processing, Computer-Assisted; Male; Pyrrolidines; Receptors, Dopamine D2; Receptors, Dopamine D3; Retrospective Studies; Tomography, Emission-Computed, Single-Photon; Young Adult

2016